UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development of a learning environment for sketching human body with pose change using Motion Capture

Procedia computer science, 2021, Vol.192, p.3696-3703

2021

Volltextzugriff (PDF)

Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women

Gastroenterology (New York, N.Y. 1943), 2016-02, Vol.150 (2), p.358-366.e8

2016

Volltextzugriff (PDF)

The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

European journal of clinical pharmacology, 2008-06, Vol.64 (6), p.605-609

2008

Volltextzugriff (PDF)

315 Effect of Ramosetron in Female Patients With Irritable Bowel Syndrome With Diarrhea: A Randomized, Placebo-Controlled Phase III Trial

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-70-S-70

2015

Volltextzugriff (PDF)

Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea

BioPsychoSocial medicine, 2017-03, Vol.11 (1), p.7-7, Article 7

2017

Volltextzugriff (PDF)

Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea

BioPsychoSocial medicine, 2017-03, Vol.11 (1), p.8-8, Article 8

2017

Volltextzugriff (PDF)

Characterization of 5-hydroxytryptamine (5-HT) receptor subtypes influencing colonic motility in conscious dogs

Naunyn-Schmiedeberg's archives of pharmacology, 1996-04, Vol.353 (5), p.489-498

1996

Volltextzugriff (PDF)

Cultural adaptation: translatability assessment and linguistic validation of the patient-reported outcome instrument for irritable bowel syndrome with diarrhea

Patient related outcome measures, 2016-01, Vol.7 (Issue 1), p.81-92

2016

Volltextzugriff (PDF)

The Irritable Bowel Syndrome-Diarrhea (IBS-D) Daily Symptom Diary and Event Log: A Newly Developed Patient-Reported Outcome (PRO) Measure

Gastroenterology (New York, N.Y. 1943), 2011, Vol.140 (5), p.S-612-S-612

2011

Volltextzugriff (PDF)

New 1, 4-Benzodiazepin-2-one Derivatives as Gastrin/Cholecystokinin-B Antagonists

Chemical and Pharmaceutical Bulletin, 1995/12/15, Vol.43(12), pp.2159-2167

1995

Volltextzugriff (PDF)

Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation

European journal of pharmacology, 1993-12, Vol.250 (2), p.303-310

1993

Volltextzugriff (PDF)

The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

European journal of clinical pharmacology, 2008-07, Vol.64 (7), p.691-695

2008

Volltextzugriff (PDF)

Biological Activity of Analogues of YM022. Novel (3-Amino Substituted Phenyl)urea Derivatives of 1, 4-Benzodiazepin-2-one as Gastrin : Cholecystokinin-B Receptor Antagonists

Chemical and Pharmaceutical Bulletin, 1996/07/15, Vol.44(7), pp.1412-1414

1996

Volltextzugriff (PDF)

Pharmacological and clinical profile of ramosetron hydrochloride (Irribow®), a novel therapeutic agent for irritable bowel syndrome with diarrhea

Folia Pharmacologica Japonica, 2009, Vol.133(5), pp.281-291

2009

Volltextzugriff (PDF)

(3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H- 1,4-benzodiazepin-3-yl)-N‘-(3-(methylamino)phenyl)urea (YF476): A Potent and Orally Active Gastrin/CCK-B Antagonist

Journal of medicinal chemistry, 1997-01, Vol.40 (3), p.331-341

1997

Volltextzugriff (PDF)

Gastrin/CCK-B receptor antagonists for a novel antiulcer agent

Folia Pharmacologica Japonica, 1995, Vol.106(3), pp.171-179

1995

Volltextzugriff (PDF)

Mechanisms of cisplatin- and m-chlorophenylbiguinide-induced emesis in ferrets

European journal of pharmacology, 1993-07, Vol.238 (2), p.369-376

1993

Volltextzugriff (PDF)

新規下痢型過敏性腸症候群治療薬ラモセトロン塩酸塩（イリボー®錠）の薬理学的特徴および臨床試験成績

日本薬理学雑誌, 2009, Vol.133(5), pp.281-291

2009

Volltextzugriff (PDF)

Effect of a selective 5-HT3 receptor agonist on gastric motility in fasted and fed dogs

European journal of pharmacology, 1997-05, Vol.327 (2-3), p.189-193

1997

Volltextzugriff (PDF)

Effect of a gastrin/CCK-B receptor antagonist YM022 on gastric emptying

Japanese Journal of Pharmacology, 1996, Vol.71 (suppl.1), p.110-110

1996

Volltextzugriff (PDF)

Effect of a selective 5-HT 3 receptor agonist on gastric motility in fasted and fed dogs

European journal of pharmacology, 1997, Vol.327 (2), p.189-193

1997

Volltextzugriff (PDF)

L-365, 260, a Potent CCK-B/Gastrin Receptor Antagonist, Suppresses Gastric Acid Secretion Induced by Histamine and Bethanechol as Well as Pentagastrin in Rats

The Japanese Journal of Pharmacology, 1992, Vol.58(2), pp.137-145

1992

Volltextzugriff (PDF)

Antisecretory and Antiulcer Effects of YM020, a New H+,K+-ATPase Inhibitor, in Rats and Dogs

The Japanese Journal of Pharmacology, 1995, Vol.67(1), pp.59-67

1995

Volltextzugriff (PDF)

New drugs against gastric acid secretion, gastrin/cholecystokinin-B receptor antagonists

Japanese Journal of Pharmacology, 1993, Vol.61 (suppl.1), p.60-60

1993

Volltextzugriff (PDF)

Antagonistic Effect of YM022, an Antiulcer Agent in Rats, on Human Cholecystokinin (CCK)B/Gastrin Receptor

The Japanese Journal of Pharmacology, 1996, Vol.71(4), pp.307-313

1996

Volltextzugriff (PDF)

1 – 25 von 152

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(87)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Englisch
(129)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(63)
Life Sciences & Biomedicine
(51)
Male
(31)
Animals
(26)
Pharmacology & Pharmacy
(23)
Biological And Medical Sciences
(22)
Humans
(19)
Medical Sciences
(19)
Female
(18)
Pharmacology. Drug Treatments
(17)
Rats
(17)
Physical Sciences
(14)
Chemistry
(13)
Digestive System
(11)
Gastric Acid - Metabolism
(11)
Dose-Response Relationship, Drug
(10)
Adult
(9)
Dogs
(9)
Middle Aged
(9)
Receptors, Cholecystokinin - Antagonists & Inhibitors
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Development of a learning environment for sketching human body with pose change using Motion Capture

Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women

The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

315 Effect of Ramosetron in Female Patients With Irritable Bowel Syndrome With Diarrhea: A Randomized, Placebo-Controlled Phase III Trial

Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea

Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea

Characterization of 5-hydroxytryptamine (5-HT) receptor subtypes influencing colonic motility in conscious dogs

Cultural adaptation: translatability assessment and linguistic validation of the patient-reported outcome instrument for irritable bowel syndrome with diarrhea

The Irritable Bowel Syndrome-Diarrhea (IBS-D) Daily Symptom Diary and Event Log: A Newly Developed Patient-Reported Outcome (PRO) Measure

New 1, 4-Benzodiazepin-2-one Derivatives as Gastrin/Cholecystokinin-B Antagonists

Comparison of the effects of trimebutine and YM114 (KAE-393), a novel 5-HT3 receptor antagonist, on stress-induced defecation

The effect of fluvoxamine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects

Biological Activity of Analogues of YM022. Novel (3-Amino Substituted Phenyl)urea Derivatives of 1, 4-Benzodiazepin-2-one as Gastrin : Cholecystokinin-B Receptor Antagonists

Pharmacological and clinical profile of ramosetron hydrochloride (Irribow®), a novel therapeutic agent for irritable bowel syndrome with diarrhea

(3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H- 1,4-benzodiazepin-3-yl)-N‘-(3-(methylamino)phenyl)urea (YF476): A Potent and Orally Active Gastrin/CCK-B Antagonist

Gastrin/CCK-B receptor antagonists for a novel antiulcer agent

Mechanisms of cisplatin- and m-chlorophenylbiguinide-induced emesis in ferrets

新規下痢型過敏性腸症候群治療薬ラモセトロン塩酸塩（イリボー®錠）の薬理学的特徴および臨床試験成績

Effect of a selective 5-HT3 receptor agonist on gastric motility in fasted and fed dogs

Effect of a gastrin/CCK-B receptor antagonist YM022 on gastric emptying

Effect of a selective 5-HT 3 receptor agonist on gastric motility in fasted and fed dogs

L-365, 260, a Potent CCK-B/Gastrin Receptor Antagonist, Suppresses Gastric Acid Secretion Induced by Histamine and Bethanechol as Well as Pentagastrin in Rats

Antisecretory and Antiulcer Effects of YM020, a New H+,K+-ATPase Inhibitor, in Rats and Dogs

New drugs against gastric acid secretion, gastrin/cholecystokinin-B receptor antagonists

Antagonistic Effect of YM022, an Antiulcer Agent in Rats, on Human Cholecystokinin (CCK)B/Gastrin Receptor

Suchergebnisse filtern